BAY38-9456 - Pivotal Trial for Diabetes Patient

Summary

The superiority of BAY 38-9456 10 mg and 20 mg regimens to placebo, and of 20 mg to 10 mg was confirmed in patients with diabetes mellitus suffering from erectile dysfunction. There was no large difference in incidence rate of drug-related adverse events between 10 mg and 20 mg regimens. Overall the tolerability was considered good with both regimens.

Timeline

Start

2004-01

Primary completion

—

Completion

2004-11

Drugs

Indications